Close menu




February 20th, 2025 | 07:30 CET

Multiplier potential with AI newcomer NetraMark! Palantir and BioNTech in one share!

  • AI
  • Technology
  • data
  • Biotechnology
Photo credits: Bayer AG

"Game changer!" "Quantum leap!" "Revolution!" Experts use numerous superlatives to describe the possibilities of Artificial Intelligence (AI) in medicine. What is certain is that AI offers tremendous potential to develop new medications faster and more cost-effectively. Pharmaceutical companies can save billions, and patients can be cured more quickly. The market for AI in medicine is expected to see significant double-digit growth rates in the coming years. NetraMark Holdings aims to profit from this megatrend. The AI specialist is on the verge of a breakthrough and is starting 2025 with a software update, an important partnership, and reinforcements in top management. The share price has jumped but remains a hidden gem and is anything but expensive. There is significant upside potential!

time to read: 3 minutes | Author: Fabian Lorenz
ISIN: NETRAMARK HOLDINGS INC | CA64119M1059 , PALANTIR TECHNOLOGIES INC | US69608A1088 , BIONTECH SE SPON. ADRS 1 | US09075V1026

Table of contents:


    NetraMark Holdings: AI hidden gem set for a breakthrough in 2025

    NetraMark is still an AI hidden gem. However, this could change dramatically soon, as evidenced by the Company's news flow and share price jump. There is now also liquid trading on German stock exchanges. Yet the technology company is still valued at less than CAD 100 million. In the current year, the operational breakthrough in the billion-dollar market is expected to be achieved. How this will happen will be presented by the Company on February 25, 2025, at the virtual investor conference IIF. Free registration here).

    What does NetraMark Holdings do? The technology company wants to revolutionize the way clinical trials are conducted in the biotech and pharmaceutical industry. To do this, it has developed software based on artificial intelligence (AI) and machine learning (ML). Using a novel topology-based algorithm, patient data sets can be broken down into subsets of strongly linked individuals based on several variables. As a result, NetraMark can work with much smaller data sets to categorize diseases into different types, classify patients for drug sensitivity, and, of course, evaluate treatment efficacy.

    NetraMark has the answer to a major challenge in AI for clinical trials. AI and ML models thrive on huge amounts of data, but clinical trials usually involve a few hundred patients. However, thanks to the NetraMark algorithm, even these smaller datasets are sufficient to provide real value to customers: finding the intersection between efficacy and feasibility to improve decision-making, shorten trial times, and ultimately reduce costs and bring the drug to market faster.

    Last week, the latest version, NetraAI 2.0, was presented to analyze and improve clinical studies. With just 30 patients, a meaningful patient group can already be established. This is a major advantage because patient recruitment often poses significant challenges for the timeline and budget. Reporting for decision-makers has also been optimized with NetraAI 2.0. Among other features, the AI reports its results after prioritization. In addition, the software provides real-time insights into the progress during the study and checks compliance with the study objectives. This allows for quick action if needed. Recommendations are also given for dose selection. Overall, NetraMark should attract numerous new customers with NetraAI 2.0 in the current year.

    Top 5 company as a reference customer

    NetraMark has also managed to secure a strong reference customer. The collaboration with a Top 5 company in the industry began in 2025. The pharmaceutical company will use the NetraAI software in the pilot project to improve the development of new therapeutics for the treatment of autoimmune diseases. NetraAI will analyze critical research areas, including the effects of drugs, surgical and medical interventions in the past, and the refinement of subtypes of autoimmune diseases. The insights gained will drive innovation in treatment strategies and patient care.

    AI in medicine: A market worth billions

    With the ability to draw important conclusions from studies with just a few patients, NetraMark has a real competitive advantage and great opportunities in a market worth billions. In 2024, around USD 3 billion is expected to have been generated with AI in the pharmaceutical industry. In 2029, it is expected to be around USD 18 billion (source: Mordorintelligence.com). This would mean that the market would grow by an impressive 42.7% per year. The growth prospects in the clinical research sub-sector are also impressive. Between 2021 and 2029, revenues from the use of AI are expected to increase from USD 1.3 billion to USD 5.6 billion.

    Top management strengthened and financing secured

    Just in time for the new software and the top customer, NetraMark has strengthened its top management and secured financing. Dr. Angelico Cart has been appointed Chief Strategy Officer. He is co-founder of Worldwide Clinical Trials and has more than 35 years of experience in clinical research and pharmaceutical strategy. This means he knows exactly what potential customers expect and can influence the further development of the software accordingly. P.J. Haley is also new to the board. He comes from the pharmaceutical industry and has over 20 years of experience in oncology commercialization, market access, and strategic partnerships. Accordingly, Haley is expected to drive NetraMark's expansion in oncology.

    NetraMark has also already secured the growth financing. At the beginning of the year, the AI company received around CAD 1.16 million through the exercise of warrants and stock options.

    Conclusion: AI stock with multiplication potential

    NetraMark's stock has significant multiplication potential. The Company is active in a growing billion-dollar market and possesses a competitive advantage with its ability to deliver added value from smaller data sets within clinical trials. The first top company has been secured as a customer. If the positive development continues, the stock, with a market capitalization of under CAD 100 million, represents a real bargain.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Stefan Feulner on November 20th, 2026 | 05:55 CET

    Merck KGaA, BioNxt Solutions and Novartis – A billion-dollar market is being reshaped

    • Biotechnology

    Multiple sclerosis has long been a billion-dollar market. But as established drugs come under pressure from expiring patents, new therapeutic approaches are advancing through clinical development. The focus is not just on better active ingredients, but increasingly on easier ways of administering treatments. A German pharmaceutical group is battling generic competition, a small biotech developer is betting on a new drug delivery format, and a Swiss industry giant has reported promising Phase 3 data. This creates significant opportunities for investors, each with a different risk profile.

    Read

    Commented by Jens Castner on November 19th, 2026 | 05:33 CET

    Gold diggers and shovel sellers: SpaceX, Amazon and HPQ Silicon in the race for internet from space

    • Spaceflight
    • Satellites
    • Batteries
    • Technology
    • Data centres
    • Rechargeable batteries
    • SpaceX
    • Amazon
    • HPQ Silicon

    Created and published on behalf of HPQ Silicon

    A spacecraft lands in the launch tower's mechanical arms, while another rocket carrying 40 satellites crashes into the sea. Rarely has the race for internet dominance in space received so much media attention as it did last weekend. SpaceX and Amazon are investing billions in orbital networks and have a combined market value of around USD 4.7 trillion. But, as in every gold rush, it is primarily the shovel sellers who stand to benefit most. HPQ Silicon aims to take on that role. The little-known Canadian company has a stock market value that is only a fraction of what the two giants are worth.

    Read

    Commented by Carsten Mainitz on November 19th, 2026 | 05:20 CET

    Uranium and Reactor Technology: Standard Uranium, Cameco and SGL Carbon – Who Benefits Most from the Nuclear Comeback?

    • Uranium
    • Nuclear power
    • Nuclear energy
    • Reactors
    • Reactor technology
    • AI
    • Supply chains

    Nuclear power needs fresh supplies! Longer operating lifetimes, new reactors and power-hungry data centres are strengthening demand and fuelling optimism for the industry. Geopolitical tensions are pushing operators to secure supplies, while additional supply requires substantial capital and time. For investors, this opens up opportunities along the entire nuclear value chain. Standard Uranium starts at the very beginning, exploring for new deposits in Canada's Athabasca region. Cameco already generates revenue from uranium and fuel services and is also involved in reactor technology through Westinghouse. SGL Carbon, in turn, supplies speciality graphite for X-energy's reactors and recently secured another order worth around USD 90 million. Which company will take off now?

    Read